- Home
- DMO vs ANVS Comparison
DMO vs ANVS Comparison
Compare DMO & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMO | ANVS |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.8M | 111.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DMO | ANVS |
|---|---|---|
| Price | $11.00 | $3.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 49.6K | ★ 797.5K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 12.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.00 | $1.11 |
| 52 Week High | $11.80 | $5.60 |
Technical Indicators
Market Signals| Indicator | DMO | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 31.93 | 45.39 |
| Support Level | $11.06 | $3.49 |
| Resistance Level | $11.08 | $3.72 |
| Average True Range (ATR) | 0.11 | 0.33 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 6.25 | 2.68 |
Price Performance
Historical ComparisonAbout DMO Western Asset Mortgage Opportunity Fund Inc.
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.